NCT05552976 2026-03-17
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
Clinical Trials
11 trialsNCT06615479 2026-03-17
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT05572515 2026-02-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05675449 2026-01-26
MagnetisMM-20
Pfizer
Phase 1 Recruiting
NCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
NCT02512926 2025-10-15
POE14-01
Stanford University
Phase 1 Completed
NCT04176718 2025-10-07
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Massachusetts General Hospital
Phase 2 Recruiting
NCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
NCT02899052 2025-08-05
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
AbbVie
Phase 2 Active not recruiting
NCT06055075 2025-07-14
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1/2 Completed
NCT02332850 2025-05-01
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Active not recruiting